Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Imaging Canada Liquidating Corp IMRSQ

IMRIS Inc designs, manufactures and markets Image-guided therapy systems that improves the effectiveness of therapy delivery. Its main product is the Visius surgical theater. The company provides its products to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. The firm is focused on bringing enhanced visualization to the point of therapy delivery and is spread across Canada, United States, Europe and the Middle East and Asia-Pacific.


GREY:IMRSQ - Post by User

Post by trader2dayon Jan 01, 2015 9:29pm
243 Views
Post# 23278636

Symbis Robotic Surgical System at FDA's doorstep

Symbis Robotic Surgical System at FDA's doorstep

Symbis Robotic Surgical System at FDA

At the current rate of incline on the chart the price moved up over $1 in less then 7 trading days. At that pace if this volume continues the price will be entering $2 on or near January 12th 2015

Chart shows next break through level at $1.30 on the decline side of the chart. FDA now will be reading the study submission for the new Symbis ( Robotic) surgical system.

A new medical frontier is now at the door of the FDA.

Imris Inc. : Approximately 4,840,200 shares changed hands, a 1,044.5 percent increase over its 65-day average volume. The shares rose $.14 or 19.1 percent to $.84


<< Previous
Bullboard Posts
Next >>